Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells.
about
Exosomes: The Link between GPCR Activation and Metastatic Potential?Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis.Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growthDistinct prostate cancer-related mRNA cargo in extracellular vesicle subsets from prostate cell lines.Technological advances in precision medicine and drug development.Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells.Pathogenic roles of microvesicles in diabetic retinopathy.Metastatic state of parent cells influences the uptake and functionality of prostate cancer cell-derived extracellular vesicles.Extracellular vesicles in breast cancer drug resistance and their clinical application.From structures to functions: insights into exosomes as promising drug delivery vehicles.Exosomal formulation of anthocyanidins against multiple cancer types.Bulk immunoassays for analysis of extracellular vesicles.Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells.Exosomes in cancer theranostic: Diamonds in the rough.The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy.Extracellular vesicles in the tumor microenvironment: Therapeutic resistance, clinical biomarkers, and targeting strategies.Peptidylarginine Deiminases-Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release?Chloramidine/Bisindolylmaleimide-I-Mediated Inhibition of Exosome and Microvesicle Release and Enhanced Efficacy of Cancer Chemotherapy.A new bioluminescent reporter system to study the biodistribution of systematically injected tumor-derived bioluminescent extracellular vesicles in mice.Exosomes in diagnosis and therapy of prostate cancer.Extracellular Microvesicles as Game Changers in Better Understanding the Complexity of Cellular Interactions-From Bench to Clinical Applications.Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model.Extracellular vesicles, exosomes and shedding vesicles in regenerative medicine - a new paradigm for tissue repair.Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics.Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity.Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models.Janus-Faced Myeloid-Derived Suppressor Cell Exosomes for the Good and the Bad in Cancer and Autoimmune Disease.Real-Time Label-Free Monitoring of Nanoparticle Cell Uptake.An Update on in Vivo Imaging of Extracellular Vesicles as Drug Delivery Vehicles.Exosomes in cancer: small vesicular transporters for cancer progression and metastasis, biomarkers in cancer therapeutics.Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management.Therapeutic Prospects of Extracellular Vesicles in Cancer Treatment.Recent advancements in the use of exosomes as drug delivery systemsEncapsulation and Delivery of Neutrophic Proteins and Hydrophobic Agents Using PMOXA-PDMS-PMOXA Triblock PolymersomesCannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in CancerEngineering exosomes: a new direction for anticancer treatment
P2860
Q26752479-1D49907D-9530-4428-BFB2-2329A0AFE27BQ30366990-A932EEF2-50CB-4B77-90E9-35CCDCCB3E10Q30845562-CB00184D-2E91-4AC3-9582-A0D390FCB182Q33588245-E7F403C2-08BA-4943-B433-49F09ACA9154Q36265498-1F0FB329-7C2D-4722-8922-DFE6462C6251Q37244501-F353A0C6-128F-4AD1-99D1-E143E2D704F6Q37493509-4F03EA2B-4B3E-4CC6-B727-F2C4A23EFFE9Q38656787-BD544129-1294-4758-817F-F7D221770BB3Q38694648-49555B6C-A0C0-4ADE-A223-D61F64650E6CQ38707369-03339091-9321-433E-9DCC-0C5CCCCE49A6Q38775093-DFB96190-C710-4B1F-87DF-D940509DD7C7Q38959552-D1F23A80-85B6-4CD6-B0D5-877FE542EADEQ39094989-B3A0A8CC-56D5-4C43-ADAD-DF5D52CC021BQ39105855-4D92CF9F-EE3F-495F-A92A-E250F90C5D8AQ39122582-D440F8CC-1AC9-492D-8925-6B57FECA1006Q39155959-FB32EC8D-21A5-457D-9BD7-C22F38833293Q39354309-5A8DA5FB-B711-44BC-B54F-E1CEAA527CEAQ39354673-0C813382-3F61-4F09-BD16-E783C43C5C01Q42229140-1C4A1584-B6D1-4A45-A7F8-D97E4B0220F1Q47095693-0A9B7A2E-80FD-45B8-B9DC-F0A2B4A46662Q47117604-7385B640-2C0F-40AF-91DF-993FB684B6C5Q47134285-854C2BC3-F861-4C9A-915C-C8A632A0427DQ47236063-4CE4874A-B25E-42EB-B0A9-9FDC46E0584AQ47304481-BFD89344-F2BB-40B9-BD38-FCB513FADFC3Q47622996-629D9A91-F398-4C5C-BCF0-66A3F0B58F73Q47741822-7DCCB619-E50F-4A9C-88D1-7C6F63E4564AQ47957249-A9BFE0B6-2662-4C01-89E9-41C010FEA9FBQ48600293-6F0812C2-4E8B-4D37-836B-5461B0B7F3EBQ49884887-077E4B5F-6723-482E-9B46-82A0D31D0F9FQ50227934-EC3C4642-0E4B-4758-9662-CCB154FD9C42Q55004583-FB18A086-16C9-4812-B2BC-10C2BFA0A43EQ55253817-749FB471-9111-4B76-96E6-4FE31025C453Q55342189-10ABEB1F-F636-4CBB-8FB5-F7A65B604B98Q55716665-A194D6D3-5E50-4194-ADAC-FBA54570A912Q57458410-442D5077-09EB-4AE7-A90C-BE9DB6A4A0CEQ58580983-A9ACE76D-42B7-4C8A-A0C3-B6CC4081C904Q58785789-C4F3C3F2-D9E5-408D-9C9A-CD878A00A21DQ58804582-49A14F66-95A7-4291-BA07-FD07EF8649BF
P2860
Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Microvesicle- and exosome-medi ...... ologous prostate cancer cells.
@en
type
label
Microvesicle- and exosome-medi ...... ologous prostate cancer cells.
@en
prefLabel
Microvesicle- and exosome-medi ...... ologous prostate cancer cells.
@en
P50
P1476
Microvesicle- and exosome-medi ...... ologous prostate cancer cells.
@en
P2093
Marjo Yliperttula
P304
P356
10.1016/J.JCONREL.2015.09.031
P407
P577
2015-09-18T00:00:00Z